OBJECTIVE: Apolipoprotein (apo) A-V is a low abundance protein with a profound influence on plasma triacylglycerol levels. In human populations, single nucleotide polymorphisms and mutations in APOA5 positively correlate with hypertriglyceridemia. As an approach to preventing the deleterious effects of chronic hypertriglyceridemia, apoA-V gene therapy has been pursued. METHODS AND RESULTS: Recombinant adeno-associated virus (AAV) 2/8 harboring the coding sequence for human apoA-V or a control AAV2/8 was transduced into hypertriglyceridemic apoa5 (-/-) mice. After injection of 1×10(12) viral genome AAV2/8-apoA-V, maximal plasma levels of apoA-V protein were achieved at 3 to 4 weeks, after which the concentration slowly declined. Complementing the appearance of apoA-V was a decrease (50±6%) in plasma triacylglycerol content compared with apoa5 (-/-) mice treated with AAV2/8-β-galactosidase. After 8 weeks the mice were euthanized and plasma lipoproteins separated. AAV2/8-apoA-V-transduced mice displayed a dramatic reduction in very low-density lipoprotein triacylglycerol content. Vector generated apoA-V in plasma associated with both very low-density lipoprotein and high-density lipoprotein fractions. CONCLUSIONS: Taken together, the data show that gene transfer of apoA-V improves the severe hypertriglyceridemia phenotype of apoa5 (-/-) mice. Given the prevalence of hypertriglyceridemia, apoA-V gene therapy offers a potential strategy for maintenance of plasma triacylglycerol homeostasis.
OBJECTIVE:Apolipoprotein (apo) A-V is a low abundance protein with a profound influence on plasma triacylglycerol levels. In human populations, single nucleotide polymorphisms and mutations in APOA5 positively correlate with hypertriglyceridemia. As an approach to preventing the deleterious effects of chronic hypertriglyceridemia, apoA-V gene therapy has been pursued. METHODS AND RESULTS: Recombinant adeno-associated virus (AAV) 2/8 harboring the coding sequence for humanapoA-V or a control AAV2/8 was transduced into hypertriglyceridemicapoa5 (-/-) mice. After injection of 1×10(12) viral genome AAV2/8-apoA-V, maximal plasma levels of apoA-V protein were achieved at 3 to 4 weeks, after which the concentration slowly declined. Complementing the appearance of apoA-V was a decrease (50±6%) in plasma triacylglycerol content compared with apoa5 (-/-) mice treated with AAV2/8-β-galactosidase. After 8 weeks the mice were euthanized and plasma lipoproteins separated. AAV2/8-apoA-V-transduced mice displayed a dramatic reduction in very low-density lipoprotein triacylglycerol content. Vector generated apoA-V in plasma associated with both very low-density lipoprotein and high-density lipoprotein fractions. CONCLUSIONS: Taken together, the data show that gene transfer of apoA-V improves the severe hypertriglyceridemia phenotype of apoa5 (-/-) mice. Given the prevalence of hypertriglyceridemia, apoA-V gene therapy offers a potential strategy for maintenance of plasma triacylglycerol homeostasis.
Authors: Len A Pennacchio; Michael Olivier; Jaroslav A Hubacek; Ronald M Krauss; Edward M Rubin; Jonathan C Cohen Journal: Hum Mol Genet Date: 2002-11-15 Impact factor: 6.150
Authors: H N van der Vliet; M G Sammels; A C Leegwater; J H Levels; P H Reitsma; W Boers; R A Chamuleau Journal: J Biol Chem Date: 2001-09-27 Impact factor: 5.157
Authors: Peter J O'Brien; William E Alborn; John H Sloan; Maverick Ulmer; Amechand Boodhoo; Michael D Knierman; Albert E Schultze; Robert J Konrad Journal: Clin Chem Date: 2004-11-04 Impact factor: 8.327
Authors: L A Pennacchio; M Olivier; J A Hubacek; J C Cohen; D R Cox; J C Fruchart; R M Krauss; E M Rubin Journal: Science Date: 2001-10-05 Impact factor: 47.728
Authors: Philippa J Talmud; Steve Martin; Marja-Riitta Taskinen; M Heikki Frick; Markku S Nieminen; Y Antero Kesäniemi; Amos Pasternack; Steve E Humphries; Mikko Syvänne Journal: J Lipid Res Date: 2004-01-16 Impact factor: 5.922
Authors: Jennifer A Beckstead; Michael N Oda; Dale D O Martin; Trudy M Forte; John K Bielicki; Trish Berger; Robert Luty; Cyril M Kay; Robert O Ryan Journal: Biochemistry Date: 2003-08-12 Impact factor: 3.162
Authors: Guang-Ping Gao; Mauricio R Alvira; Lili Wang; Roberto Calcedo; Julie Johnston; James M Wilson Journal: Proc Natl Acad Sci U S A Date: 2002-08-21 Impact factor: 11.205
Authors: Vineeta Sharma; Andrzej Witkowski; H Ewa Witkowska; Andrew Dykstra; Jens B Simonsen; Lisa Nelbach; Jennifer A Beckstead; Clive R Pullinger; John P Kane; Mary J Malloy; Gordon Watson; Trudy M Forte; Robert O Ryan Journal: Arterioscler Thromb Vasc Biol Date: 2014-08-14 Impact factor: 8.311
Authors: Linda S Zhang; Min Xu; Qing Yang; Robert O Ryan; Philip Howles; Patrick Tso Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-01-23 Impact factor: 4.052